Introduction
============

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, accounting for 80% of all digestive mesenchymal tumors. It is widely accepted that GISTs arise from the interstitial cells of Cajal, and the term 'stromal tumor' was first introduced by Mazur and Clark in 1983 ([@b1-ol-0-0-9320]). The incidence of GISTs has been reported to range between 11 and 15 per million annually ([@b2-ol-0-0-9320]--[@b4-ol-0-0-9320]), and 60% of GISTs are located in the stomach, 30% in the jejunum or ileum, 5% in the duodenum and 4% in the colorectum. Extragastrointestinal GISTs (EGISTs) have been reported in the liver, omentum, mesentery, gallbladder and urinary bladder ([@b5-ol-0-0-9320]--[@b7-ol-0-0-9320]).

The diagnosis of GISTs is based on morphology, positive immunohistochemistry (IHC) results for CD117 and DOG1, and mutation analyses of KIT and platelet-derived growth factor receptor α polypeptide gene (PDGFRA) ([@b7-ol-0-0-9320]--[@b9-ol-0-0-9320]). With increasing use of abdominal computed tomography (CT), magnetic resonance imaging (MRI) and endoscopy, an increasing number of asymptomatic GISTs are diagnosed at an early stage, although the effect of early detection of GIST on the prognosis remains unclear. The National Institutes of Health (NIH) and Armed Forces Institute of Pathology (AFIP) risk classification criteria are commonly used to predict the prognosis of GISTs ([@b10-ol-0-0-9320]--[@b12-ol-0-0-9320]). Large tumor size, high mitotic rate, non-gastric tumor location and tumor ulceration are commonly accepted to be associated with a poor prognosis in patients with GIST. Other factors, including sex, age, symptoms and IHC results are also reported to be associated with patient outcomes ([@b13-ol-0-0-9320],[@b14-ol-0-0-9320]). However, the biological behavior of GISTs varies widely, with unclear risk predictors, and it is difficult to predict their malignant potential with the currently available risk classification criteria ([@b15-ol-0-0-9320]).

The number of studies on the clinicopathological characteristics of GIST in China is limited. The aim of the present study was to update the clinicopathological and immunophenotypic characteristics of GISTs in mainland China, and to investigate the prognostic factors of GISTs based on these patients.

Materials and methods
=====================

### Patients and diagnosis

The present study was approved by the Institutional Review Board of Changzheng Hospital. Written informed consent was obtained from all patients involved for the publication of any associated data and accompanying images. The clinicopathological and survival data of 182 patients with GIST treated surgically at Shanghai Changzheng Hospital between January 2011 and December 2014 were retrospectively reviewed. A total of 94 males and 88 females were included. The mean age of the patients was 59.2±12.6 years (range, 26--88 years). The diagnosis of each patient with GIST was established based on the results of the histopathology and IHC. Pathological samples were collected during surgical interventions. If the diagnosis of GIST was uncertain based on pathology, mutation analysis for the KIT and PDGFRA genes was performed. For 136 patients with mitotic rate data, the tumors were categorized into different risk groups according to the modified NIH and AFIP risk classification criteria.

The following details of these patients were collected: Age, sex, symptoms and signs, preoperative investigations, surgical details, pathology and follow-up data. The tumor site was analyzed according to previous classification methods ([@b16-ol-0-0-9320],[@b17-ol-0-0-9320]). Preoperative investigations comprised radiological and endoscopic examinations, including gastroscopy, abdominal CT, MRI, colonoscopy, small intestinal endoscopy, capsule endoscopy and positron emission tomography (PET)-CT.

### Pathology and IHC

Tissues were fixed in formalin for 12--24 h at room temperature then paraffin-embedded. Sections of 4 µM were stained with Hematoxylin & Eosin at room temperature (3--5 min for hematoxylin and 5--10 sec for eosin) ([@b18-ol-0-0-9320]). Tissue sections were deparaffined in xylene and rehydrated in a descending alcohol series. Antigen retrieval was performed by heating the sections for 30 min at 95°C in 1 mM EDTA buffer (pH 8.0). Endogenous peroxidase activity was eliminated by treating sections with 3% methanolic hydrogen peroxide solution for 10 min. Thereafter, the slides were blocked in 1/100 diluted goat serum (cat. no. kit-9710; Fuzhou Maixin Biotech Co., Ltd., Fuzhou China) for 20 min at room temperature. IHC analysis included common biomarkers for the diagnosis of GISTs, including CD117 (dilution, 1:400; cat. no. kit-0029; Fuzhou Maixin, Co., Ltd., Fuzhou, China), DOG1 (dilution, 1:400; cat. no. kit-0035; Fuzhou Maixin Biotech Co., Ltd.), CD34 (dilution, 1:600; cat. no. kit-0004; Fuzhou Maixin Biotech Co., Ltd.), smooth muscle actin (SMA) (dilution, 1:600 dilution; cat. no. kit-0006; Fuzhou Maixin Biotech Co., Ltd.), S-100 protein (dilution, 1:500; cat. no. kit-0007; Fuzhou Maixin Biotech Co., Ltd.), Ki-67 (dilution, 1:500; cat. no. kit-0005; Fuzhou Maixin Biotech Co., Ltd.) and desmin (dilution, 1:600; cat. no. kit-0023; Fuzhou Maixin Biotech Co., Ltd.). The sections were incubated with the aforementioned antibodies at 4°C overnight. Following 3 washes in PBS, the sections were incubated with biotin-conjugated secondary antibody (ready-to-use; 50 µl for each section; goat anti-mouse IgG secondary antibody for CD34, SMA, S-100, Ki-67 and desmin; goat anti-rabbit IgG secondary antibody for CD117 and DOG1) (cat. no. kit-9710; Fuzhou Maixin Biotech Co., Ltd.) for 10 min at room temperature, followed by incubation with peroxidase-conjugated biotin-streptavidin complex (Fuzhou Maixin Biotech Co., Ltd.) for 10 min at room temperature, and finally stained with diaminobenzidine at room temperature for 2 min, and counterstained with hematoxylin at room temperature for 3--5 min. Mitoses were counted in 50 high-power fields (HPF). Two professional pathologists reviewed these results under a light microscope (×100 and ×400, magnification).

### Treatment methods and follow-up

For localized primary GISTs, radical resection, including open surgical resection and minimally invasive techniques, were selected as the primary treatments ([@b19-ol-0-0-9320]). Minimally invasive techniques included laparoscopic surgery, endoscopic surgery and endoscopy-assisted laparoscopic surgery ([@b20-ol-0-0-9320],[@b21-ol-0-0-9320]). For locally advanced unresectable or metastatic GISTs, palliative surgery and/or imatinib treatment were recommended, and imatinib adjuvant therapy following radical resection was recommended for patients with intermediate-to-high-risk GISTs ([@b22-ol-0-0-9320]). The final treatment decision was made with the consent of the patients. The records of all surgical procedures were reviewed. Patient follow-up was conducted by regular hospital visits at 3, 6 and 12 months, and annually thereafter. Each visit included a medical review, physical examination and associated investigations. The patients\' status was confirmed by telephone communication at the end of the study. Survival outcomes were assessed in terms of overall survival (OS) and relapse-free survival (RFS). OS was defined as the time from the date of initial treatment to the date of the last follow-up or mortality, and RFS was defined as the time from the date of initial treatment to the time of clinical or radiological evidence of disease relapse or the date of the last follow-up.

### Statistical analysis

SAS 9.3 software (SAS Institute, Inc., Cary, NC, USA) and SPSS 23.0 (IBM Corp., Armonk, NY, USA) were used for statistical analysis. Continuous variables are expressed as mean ± standard deviation and were compared using an unpaired, two-tailed Student\'s t-test. Categorical variables were compared using the χ^2^ test or Fisher\'s exact test. The Kaplan-Meier method and the log-rank test were used for survival analysis. Independent factors were identified in multivariate analysis using the Cox proportional hazard model. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological characteristics

A total of 182 patients with GISTs were analyzed in the present study. The stomach was the most common site, accounting for 73.1% of the cases, followed by the jejunum and ileum (14.3%), duodenum (5.5%), colorectum and anus (4.94%), esophagus (1.1%), and EGISTs (1.1%). Abdominal pain, dyspepsia and gastrointestinal bleeding were the main presenting complaints, reported in 30.2, 23.1 and 21.4% of the patients, respectively. The symptoms varied according to the primary location. Patients with esophageal GISTs often presented with dysphagia (2/2 patients), whereas patients with GISTs of the colorectum or anal canal usually reported altered bowel habits (4/9 patients; [Table I](#tI-ol-0-0-9320){ref-type="table"}).

Gastroscopy and abdominal CT were used in 83 (54.6%) and 87 (57.2%) patients, respectively, with a high diagnostic accuracy of 62.7 and 74.7%, respectively. Other investigations, including endoscopic ultrasonography, MRI, abdominal ultrasound, colonoscopy, small intestinal endoscopy (or capsule endoscopy) and PET-CT were used in 23 (15.1%), 13 (8.6%), 32 (21.1%), 8 (5.3%), 7 (4.6%) and 5 (3.3%) patients, respectively ([Table I](#tI-ol-0-0-9320){ref-type="table"} and [Fig. 1](#f1-ol-0-0-9320){ref-type="fig"}). In addition, 30 patients (16.5%) were diagnosed with GIST by pathological examination following surgery for other conditions.

The majority of GIST samples were positive for CD117 and DOG1 according to the IHC analysis (98.4 and 98.3% cases, respectively). In addition, 94.5% of the samples were positive for CD34. Positive SMA, S-100 protein and desmin expression was also detected in 57.5, 14.2 and 13.9% of the GISTs, respectively. The Ki-67 index was 0--65%, with a mean of 7% ([Table I](#tI-ol-0-0-9320){ref-type="table"} and [Fig. 2](#f2-ol-0-0-9320){ref-type="fig"}).

The malignant potential of 136 GISTs with data on mitotic rate was evaluated. The distribution of risk groups was 17 (12.5%) in the very low-risk, 35 (25.7%) in the low-risk, 31 (22.8%) in the intermediate-risk and 53 (39.0%) in the high-risk groups according to the NIH criteria. In addition, 72 cases (52.9%) were classified in the benign group, 5 (3.68%) in the malignant potential group and 59 (43.4%) in the malignancy group according to the AFIP criteria. It was also demonstrated that larger GISTs exhibited a higher mitotic rate (P\<0.001). The NIH risk classification of GISTs at different sites was significantly different (P=0.006), with GISTs in the stomach or duodenum exhibiting a lower risk of malignancy. However, the AFIP risk classification and mitotic rate of GISTs did not differ significantly by primary location (P=0.0996 and P=0.1203, respectively). Based on the symptoms of the 136 patients when they were admitted to Changzheng Hospital, the patients were divided into the asymptomatic GIST group (asymptomatic patients and patients accidentally diagnosed with co-existing disease; n=46) and the symptomatic GIST group (n=90). Patients in the asymptomatic group had a smaller tumor size (P=0.0245) and a lower risk of malignancy according to the NIH (P=0.0327) and AFIP (P=0.0198) risk classification criteria ([Tables II](#tII-ol-0-0-9320){ref-type="table"} and [III](#tIII-ol-0-0-9320){ref-type="table"}).

### Treatment

Numerous surgical procedures were performed, including partial gastric resection, total gastric resection, partial intestinal resection, hemicolectomy, sigmoid colon resection, abdomino-perineal rectum resection, pancreatoduodenectomy, distal pancreatectomy and endoscopic submucosal dissection. The choice of surgical procedure was individualized, depending on the tumor location, size and possibility of complete resection. Excluding the 30 patients who were incidentally diagnosed with GIST while treated for other conditions, 125 of the remaining 152 patients underwent radical resection of the primary tumor. Among these patients, 71 underwent open surgical resection; 47 underwent laparoscopic resection; 3 underwent endoscopic surgery; and 4 underwent endoscopic-assisted laparoscopic surgery. An additional 27 patients with unresectable tumors received palliative surgery, including 19 open surgery and 8 laparoscopic surgery. In 24 of the patients, the tumors displayed clear malignant characteristics during surgery, including local invasion and metastasis. Additionally, 5 patients were revealed to have tumor bleeding and ulceration. Imatinib as adjuvant therapy was administered to 15 patients with intermediate-to-high-risk GISTs, including 6 patients with advanced disease. No neoadjuvant imatinib therapy was used in the patients enrolled in the present study.

### Survival analysis

Based on the 152 patients without co-existing diseases, the median follow-up time was 48 months (range, 3--81 months), and the 5-year OS and RFS rates were 85.4% (95% CI: 79.5--91.3) and 83.8% (95% CI: 77.5--90.1), respectively. A total of 21 patients succumbed during the follow-up period as a result of various causes (disease progression, other chronic diseases, including diabetes mellitus, cardiovascular and cerebral disorders, other malignancies and trauma). A total of 4 patients developed metastases in the abdominopelvic cavity and 3 in the liver during follow-up. The results of the univariate analysis of potential prognostic factors are presented in [Table IV](#tIV-ol-0-0-9320){ref-type="table"} and [Fig. 3](#f3-ol-0-0-9320){ref-type="fig"}. Larger tumor size (\>10 cm; P\<0.001), higher mitotic rate (\>10/50 HPF; P\<0.001), aggressive behavior, including tumor metastasis or local invasion prior to treatment (P\<0.001) and negative SMA expression (P=0.009) contributed toward poorer survival of patients with GIST. In addition, non-gastric disease location (P\<0.001), larger tumor size (\>10 cm; P\<0.001), higher mitotic rate (\>10/50 HPF; P=0.004) and aggressive behavior (P\<0.001) were associated with higher risk of recurrence. Patients receiving palliative tumor resection had a significantly shorter survival time (P\<0.001) and a higher risk of recurrence (P\<0.001). When therapeutic factors were included in the multivariate analysis, palliative surgical resection was the only independent risk factor for OS (HR=9.196, 95% CI: 3.327--25.417, P\<0.001) and RFS (HR=16.42, 95% CI: 6.065--44.454, P\<0.001). If the therapeutic factors were excluded, the multivariate analysis indicated that the mitotic rate (HR=3.761, 95% CI: 1.288--10.987, P=0.015) and aggressive behavior (HR=3.916, 95% CI: 1.389--11.044, P=0.010) were independent risk factors for OS. Non-gastric disease location (HR=4.740, 95% CI: 1.747--12.857, P=0.002) and aggressive behavior (HR=4.009, 95% CI: 1.538--10.449, P=0.004) were independent risk factors for RFS ([Table V](#tV-ol-0-0-9320){ref-type="table"}).

Discussion
==========

The present retrospective study, based on 182 Chinese patients with GIST, aimed to investigate the clinicopathological and prognostic characteristics of this disease. The results are comparable with those of previous studies in other populations ([@b23-ol-0-0-9320]--[@b27-ol-0-0-9320]). The median age of the patients in the present study was 60 years. The stomach was the most common primary site of GISTs, while patients with GIST usually lack specific symptoms. In line with the results of a Japanese study that indicated that GISTs may be incidentally discovered during gastric cancer screening ([@b28-ol-0-0-9320]), 36 patients in the present study were asymptomatic without co-existing diseases and their GISTs were detected during their annual physical exam. Radical tumor resection is the most important factor affecting patient prognosis. Furthermore, non-gastric disease location, higher mitotic rate and tumor metastasis or local invasion prior to treatment were revealed to be predictors of a poor prognosis.

For GIST patients with clinical symptoms and those with incidentally detected tumors during physical examination, further radiological and endoscopic examinations are required ([@b29-ol-0-0-9320]). In the present study, 52 patients were diagnosed with GIST by gastroscopy and 65 by abdominal CT. Gastroscopic and endoscopic ultrasonography can detect mostly intramural tumors and enable acquisition of cytological or histological samples, while the use of endoscopy is limited when evaluating metastasis outside the digestive tract ([@b30-ol-0-0-9320]). Abdominal CT can scan the whole abdomen and is able to detect small lesions, providing valuable information on the size, morphology, aggressiveness and metastasis of the tumors ([@b31-ol-0-0-9320],[@b32-ol-0-0-9320]). Abdominal MRI and PET-CT also have high diagnostic sensibility, particularly in intestinal GISTs or EGISTs, and were used in 13 and 5 patients, respectively. MRI is affected by peristalsis of the gastrointestinal tract, which limits its applicability, although it has been reported that, for lesions of the rectum and liver, MRI may offer more detailed images compared with CT ([@b33-ol-0-0-9320]). PET-CT is applied for evaluating tumor metastasis and response following the initiation of targeted therapy ([@b34-ol-0-0-9320]). Among patients with intestinal GISTs, the diagnosis of 7 patients in the present study series was confirmed by small intestinal endoscopy or capsule endoscopy, as their tumors were relatively difficult to diagnose.

There are no standard criteria for assessing the aggressive behavior and predicting the clinical prognosis of GISTs, although the NIH and AFIP criteria are widely recommended ([@b35-ol-0-0-9320]). It is commonly accepted that all GISTs are considered to have malignant potential ([@b36-ol-0-0-9320]). Through multivariate analysis, higher mitotic rate and tumor metastasis or local invasion prior to treatment were revealed to be associated with poor survival in GIST patients, and non-gastric disease location was associated with tumor recurrence, which is consistent with the results of previous studies ([@b16-ol-0-0-9320]). Similarly, one British study ([@b17-ol-0-0-9320]) identified high mitotic index as an independent poor prognostic factor in these patients. Miettinen and Lasota ([@b37-ol-0-0-9320]) also demonstrated that small intestinal GISTs behave more aggressively than gastric GISTs, and small intestinal GISTs tend to be larger and more advanced at diagnosis. Liu *et al* ([@b35-ol-0-0-9320]) suggested that gastrointestinal bleeding is a prognostic factor. However, preoperative symptoms did not appear to affect the outcome of patients with GIST in our analysis. Large tumor size is considered to be a prognostic factor in the NIH and AFIP risk classification criteria. However, it failed to be an independent risk factor in the present study. Notably, patients with SMA-negative tumors exhibited a shorter survival time. Similarly, Demir *et al* ([@b38-ol-0-0-9320]) reported that patients with SMA-positive GISTs tended to survive longer and had significantly longer disease-free survival (DFS) times than the SMA-negative cases. Fujimoto *et al* ([@b39-ol-0-0-9320]) reported no association between SMA IHC analysis and the prognosis of patients with GIST. However, Bertin *et al* ([@b40-ol-0-0-9320]) reported that SMA positivity is significantly associated with a lower 5-year survival rate (39 vs. 100%). Differences in the selected population, tumor location, disease stage and treatment between these studies may affect these conclusions.

GISTs are usually asymptomatic until they reach a large size, at which point they may cause non-specific symptoms or be detected as a palpable mass ([@b41-ol-0-0-9320]). Compared with patients diagnosed with clinical symptoms, asymptomatic patients are considered to have early-stage disease. A total of 46 patients in the present study were asymptomatic or accidentally diagnosed with co-existing disease, and these GISTs were smaller in size and exhibited a lower risk based on the NIH and AFIP risk classification criteria, although no significant effect on OS and RFS was observed. A study by Yamamoto *et al* ([@b28-ol-0-0-9320]) reported that GISTs are incidentally observed during gastric cancer screenings in Japan. Over half of these patients are asymptomatic and have smaller tumors (P\<0.001) and lower recurrence rates (P=0.017), compared with symptomatic patients. Therefore, the Japanese gastric cancer screening system contributes toward the early detection of gastric GISTs and favorable treatment outcomes by identifying asymptomatic patients. Scherubl *et al* ([@b30-ol-0-0-9320]) demonstrated that early asymptomatic GISTs have an excellent GIST-specific prognosis. The results of the present study also suggested that detecting GISTs at an early stage may improve patient outcome.

For resectable localized GISTs, radical surgery is the standard and first choice of treatment ([@b42-ol-0-0-9320]). Radical tumor resection significantly improved survival and reduced tumor recurrence, in univariate or multivariate analyses. Different surgical approaches, including open and laparoscopic surgery and endoscopic procedures, were performed in the present study. No statistically significant difference was observed in OS or RFS among these surgical strategies. A number of studies have been performed comparing the effect of minimally invasive and open surgery in the treatment of GISTs ([@b42-ol-0-0-9320]--[@b44-ol-0-0-9320]). It is generally accepted that minimally invasive surgery has similar or even superior perioperative outcomes, without compromising the oncological outcomes; it may also be safely used for larger tumors or tumors located in unfavorable sites. Imatinib serves an important role in the treatment of advanced GISTs and in the adjuvant setting, reducing the risk of recurrence and metastasis ([@b16-ol-0-0-9320],[@b45-ol-0-0-9320]). In the present study, not all the patients with intermediate-to-high risk GIST received imatinib as adjuvant therapy. However, there was no observed improvement in OS and RFS in the 15 patients who were administered adjuvant imatinib therapy. One possible reason may be that the selection of candidates for adjuvant therapy was not standardized and the sample size was limited. Imatinib was also recommended to patients receiving palliative surgery and those with disease progression. Advanced GISTs will inevitably progress and reduce the OS and RFS rates ([@b16-ol-0-0-9320]).

GISTs are widely considered to have a low risk of lymph node metastasis; therefore, lymphadenectomy is not deemed necessary during surgical resection ([@b46-ol-0-0-9320],[@b47-ol-0-0-9320]). However, GIST cases with lymph node metastasis have been reported. Tashiro *et al* ([@b48-ol-0-0-9320]) and Shafizad *et al* ([@b49-ol-0-0-9320]) reported two cases of lymph node involvement in gastric GISTs. In addition, Gong *et al* ([@b50-ol-0-0-9320]) reported that 6 of 29 (20.7%) patients with GIST were revealed to have lymph node metastasis on PET-CT imaging. In the present study, lymph node metastasis was detected in only 1 patient with a history of intestinal GIST resection 2 years prior. Palliative surgery was performed and two main masses were removed from the small intestine. Tumor ulceration and bleeding were observed intraoperatively, and liver, peritoneal and pelvic cavity metastasis were confirmed. All 7 mesenteric lymph nodes resected during surgery were positive. Despite these reports, however, GISTs rarely metastasize to the lymph nodes, and regional lymph node resection is of unproven value ([@b16-ol-0-0-9320]).

There were certain limitations to the present study: The design of the study was retrospective; the selection of surgical approach and adjuvant therapy were not standardized; and the use of imatinib as an adjuvant therapy was limited to 15 patients with a potential selection bias; therefore, the benefit of using imatinib as adjuvant therapy cannot be evaluated based on this study. In summary, the present study updated the clinicopathological and immunophenotypic characteristics of GISTs in mainland China. Asymptomatic GISTs may be of smaller size and have a lower risk of malignancy according to the NIH and AFIP risk classification criteria. Clinical and immunohistochemical results were used for survival analysis, and positive SMA was associated with an improved survival in univariate analysis. Higher mitotic rate and tumor metastasis or local invasion prior to treatment were revealed to be independent risk factors for a poor OS, whereas non-gastric disease location and aggressive behavior were independent risk factors for a poor RFS. Large tumor size, a prognostic factor in the NIH and AFIP risk classification criteria, failed to reveal significant impact on OS and RFS in multivariate analysis. The present study may aid clinicians with an improved understanding of the diagnosis and treatment of GISTs.
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![Radiological characteristics of GISTs. (A) Computed tomography scan (arterial phase): The lesion is indicated by the arrow. GIST of the stomach demonstrating a thickening of the gastric wall, with slight to moderate inhomogeneous enhancement following contrast agent injection. Lymph nodes around the mass exhibited reactive hyperplasia. (B) Magnetic resonance imaging (T2-weighted): The lesion is indicated by the arrow. GIST of the stomach sized \~9×7 cm and exhibiting heterogeneous hyperintense T2 signals. GIST, gastrointestinal stromal tumor.](ol-16-04-4905-g00){#f1-ol-0-0-9320}

![Histological and immunohistochemical characteristics of GISTs. H&E staining; magnification, (A) ×100 and (B) ×400. Strong and diffuse staining for CD117; magnification, (C) ×100 and (D) ×400. Strong and diffuse staining for CD34; magnification, (E) ×100 and (F) ×400. Staining for DOG1; magnification, (G) ×100 and (H) ×400. Staining for Ki-67; magnification, (I) ×100 and (J) ×400. GIST, gastrointestinal stromal tumor; CD, cluster of differentiation.](ol-16-04-4905-g01){#f2-ol-0-0-9320}

![Survival analysis of 152 patients. (A) OS according to tumor size (P\<0.001). (B) RFS according to tumor location (P\<0.001). OS, overall survival; RFS, relapse-free survival.](ol-16-04-4905-g02){#f3-ol-0-0-9320}

###### 

Clinical characteristics of 182 patients with gastrointestinal stromal tumor.

  Factor                                                                           n
  -------------------------------------------------------------------------------- -------------
  Sex, n (%)                                                                       
    Male                                                                             94 (51.6)
    Female                                                                           88 (48.4)
  Age, years                                                                       
    Median                                                                         60
    Range                                                                          26--88
  Location, n (%)                                                                  
    Esophagus                                                                        2 (1.10)
    Stomach                                                                        133 (73.1)
    Duodenum                                                                         10 (5.50)
    Jejunum and ileum                                                                26 (14.3)
    Colon, rectum and anus                                                           9 (4.94)
    Other (liver and omentum)                                                        2 (1.10)
  Immunohistochemistry, n (%)                                                      
    CD117                                                                          179 (98.4)
    DOG-1                                                                          177 (98.3)
    CD34                                                                           171 (94.5)
    Desmin                                                                           24 (13.9)
    S-100                                                                            25 (14.2)
    SMA                                                                            100 (57.5)
  Symptoms, n (%)                                                                  
    Abdominal pain                                                                   55 (30.2)
    Dyspepsia                                                                        42 (23.1)
    Gastrointestinal bleeding                                                        39 (21.4)
    Regurgitation                                                                    11 (6.04)
    Palpable mass                                                                    8 (4.40)
    Altered bowel habit                                                              8 (4.40)
    Weight loss                                                                      4 (2.20)
    Fever                                                                            3 (1.65)
    Dysphagia                                                                        2 (1.10)
    Vomiting                                                                         2 (1.10)
  Pre-operation examinations, n (%)^[a](#tfn1-ol-0-0-9320){ref-type="table-fn"}^   
    Gastroscopy                                                                      83 (54.6)
    Abdominal CT scan                                                                87 (57.2)
    Endoscopic ultrasonography                                                       23 (15.1)
    Abdominal MRI                                                                  13 (8.6)
    Abdominal ultrasound                                                             32 (21.1)
    Colonoscopy                                                                      8 (5.3)
    Small intestine endoscopy                                                        7 (4.6)
    PET-CT                                                                           5 (3.3)

n=152, 30 patients with co-existing diseases excluded. CD, cluster of differentiation; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography.

###### 

Association between tumor site, tumor size and mitotic rate.

  Factor                     n     0-5/50 HPF   5-10/50 HPF   \>10/50 HPF
  -------------------------- ----- ------------ ------------- -------------
  Location                                                    
    Stomach                  101   59           33            9
    Duodenum                 9     7            1             1
    Jejunum and ileum        21    10           7             4
    Colon, rectum and anus   4     0            3             1
    Omentum                  1     1            0             0
  Tumor size, cm                                              
    0--2                     15    14           1             0
    2--5                     59    36           18            5
    5--10                    40    22           16            2
    ≥10                      22    5            9             8
    Total                    136   77           44            15

###### 

Association between symptoms, tumor site and NIH or AFIP risk classification criteria.

                                   NIH   AFIP                      
  -------------------------- ----- ----- ------ ---- ---- ---- --- ----
  Location                                                         
    Stomach                  101   16    25     29   31   56   3   42
    Duodenum                 9     1     5      1    2    7    0   2
    Jejunum and ileum        21    0     5      0    16   8    1   12
    Colon, rectum and anus   4     0     0      1    3    0    1   3
    Omentum                  1     0     0      0    1    1    0   0
  Symptoms                                                         
    Asymptomatic             46    8     13     14   11   31   1   14
    Symptomatic              90    9     22     17   42   41   4   45
  Total                      136   17    35     31   53   72   5   59

NIH, National Institutes of Health; AFIP, Armed Forces Institute of Pathology.

###### 

Univariate analysis of prognostic factors for OS and RFS in 152 GIST patients.

                                                                        OS     RFS                                                           
  --------------------------------------------------------------- ----- ------ ------------------------------------------------------ ------ ------------------------------------------------------
  Sex                                                                                                                                        
    Male                                                          69    84.0   0.724                                                  81.8   0.361
    Female                                                        83    86.5                                                          85.5   
  Age (years)                                                                                                                                
    ≤60                                                           83    88.5   0.177                                                  87.1   0.360
    \>60                                                          69    81.3                                                          79.5   
  Disease location                                                                                                                           
    Gastric                                                       106   87.8   0.192                                                  90.8   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^
    Non-gastric                                                   46    79.9                                                          68.5   
  Tumor size (cm)                                                                                                                            
    ≤10                                                           129   91.1   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^   87.6   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^
    \>10                                                          23    55.3                                                          60.1   
  Mitotic rate (/50 HPF)                                                                                                                     
    ≤10                                                           107   89.3   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^   87.3   0.004^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^
    \>10                                                          14    54.5                                                          58.9   
  Metastatic disease or local invasion                                                                                                       
    Yes                                                           24    49.0   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^   44.9   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^
    No                                                            128   91.9                                                          90.2   
  Ulceration                                                                                                                                 
    Yes                                                           5     80.0   0.664                                                  80.0   0.120
    No                                                            147   85.5                                                          84.0   
  Desmin                                                                                                                                     
    Positive                                                      19    82.6   0.841                                                  85.9   0.539
    Negative                                                      130   85.7                                                          83.3   
  S-100                                                                                                                                      
    Positive                                                      23    85.6   0.907                                                  95.5   0.132
    Negative                                                      126   86.0                                                          82.1   
  SMA                                                                                                                                        
    Positive                                                      89    91.4   0.009^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^     85.4   0.448
    Negative                                                      58    76.7                                                          80.3   
  Symptom                                                                                                                                    
    Asymptomatic                                                  36    91.2   0.301                                                  93.0   0.077
    Symptomatic                                                   116   83.6                                                          81.0   
  Resection margin                                                                                                                           
    Radical                                                       125   93.4   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^   94.4   \<0.001^[a](#tfn3-ol-0-0-9320){ref-type="table-fn"}^
    Palliative                                                    27    46.6                                                          28.4   
  Surgical procedures                                                                                                                        
    Open                                                          90    82.6   0.232                                                  82.8   0.587
    Minimally invasive                                            62    89.7                                                          85.0   
  Imatinib therapy^[b](#tfn4-ol-0-0-9320){ref-type="table-fn"}^                                                                              
    Yes                                                           15    86.2   0.388                                                  54.3   0.052
    No                                                            71    77.0                                                          83.0   

Statistically significant (P\<0.05)

only including 86 patients with intermediate-high risk. SMA, smooth muscle actin, OS, overall survival, RFS, relapse-free survival; N, number.

###### 

Multivariate analysis of prognostic factors for OS and RFS in 152 patients with gastrointestinal stromal tumors (therapeutic factors excluded).

                                                            OS      RFS                                                                                          
  --------------------------------------------------------- ------- --------------- ---------------------------------------------------- ------- --------------- ----------------------------------------------------
  Disease location (gastric vs. non-gastric)                --      --              --                                                   4.740   1.747--12.857   0.002^[a](#tfn5-ol-0-0-9320){ref-type="table-fn"}^
  Mitotic rate (≤10/50 HPF vs. \>10/50 HPF)                 3.761   1.288--10.987   0.015^[a](#tfn5-ol-0-0-9320){ref-type="table-fn"}^   --      --              --
  Metastatic disease or adjacent involvement (no vs. yes)   3.916   1.389--11.044   0.010^[a](#tfn5-ol-0-0-9320){ref-type="table-fn"}^   4.009   1.538--10.449   0.004^[a](#tfn5-ol-0-0-9320){ref-type="table-fn"}^

Statistically significant. OS, overall survival; RFS, relapse-free survival; HR, hazards ratio; CI, confidence interval.

[^1]: Contributed equally
